While Eli Lilly continues to ride an historic stretch of company growth and performance in the annals of Big Pharma, the now ...

Parabilis Medicines surged 58% on its first trading day, pushing its market cap to roughly $3.7 billion and cementing its $670 million raise as the largest biotech IPO on record. Parabilis Medicines ...

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

We have entered a new era, with artificial intelligence (AI) driving one of the fastest technological transformations in ...

In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh ...

The ACCESS Model’s significance for the industry is that it introduces a new level of operational capacity to what remains ...

Venture capital, long the dominant engine of drug development, was never really built for rare disease. The returns simply don’t scale to the fund sizes venture capitalists need to justify the effort.

ACD680 modulates gamma-secretase to lower Aβ42 production and increase Aβ37/Aβ38, potentially reducing aggregation and plaque formation via upstream amyloid processing rather than plaque clearance.

Transaction terms include a $124/share all-cash tender offer, implying a 40% premium to prior close, with expected Q3 2026 closing pending antitrust and customary conditions. Regulatory timelines ...

Parabilis raised $670M via 33.5M shares at $20 and secured $75M Regeneron private placement at $18, totaling ~$745M gross proceeds ahead of Nasdaq listing. Helicon discovery platform engineers ...

Deal terms for Vega include $1.25B upfront and up to $750M sales milestones, with expected close in Q3 2026 and a projected ...